for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eisai Co., Ltd

4523.T

Latest Trade

8,351.00JPY

Change

22.00(+0.26%)

Volume

489,100

Today's Range

8,250.00

 - 

8,363.00

52 Week Range

5,205.00

 - 

9,679.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

FDA Alerts Of Possible Increased Risk Of Cancer With Weight Management Medicine Belviq, Belviq XR

Jan 14 (Reuters) - U.S. Food and Drug Administration::FDA - ALERTS THAT RESULTS FROM CLINICAL TRIAL ASSESSING SAFETY SHOW POSSIBLE INCREASED RISK OF CANCER WITH WEIGHT MANAGEMENT MEDICINE BELVIQ, BELVIQ XR.FDA SAYS AT THIS TIME, CAUSE OF CANCER "IS UNCERTAIN, AND WE CANNOT CONCLUDE" BELVIQ, BELVIQ XR (LORCASERIN) CONTRIBUTES TO CANCER RISK.

Gilead And Eisai Enter Into Agreement In Japan For Co-Promotion Of The Filgotinib

Dec 24 (Reuters) - Gilead Sciences Inc <GILD.O>::GILEAD AND EISAI ENTER INTO AGREEMENT IN JAPAN FOR THE CO-PROMOTION OF THE INVESTIGATIONAL RHEUMATOID ARTHRITIS THERAPY FILGOTINIB, PENDING REGULATORY APPROVAL.GILEAD -AGREEMENT EXTENDS TO ADDITIONAL POTENTIAL INDICATIONS FOR FILGOTINIB, INCLUDING ULCERATIVE COLITIS, CROHN'S DISEASE AND PSORIATIC ARTHRITIS.GILEAD SCIENCES-THROUGH THIS COLLABORATION, GILEAD JAPAN WILL RETAIN RESPONSIBILITY FOR MANUFACTURING AND MARKETING APPROVAL OF FILGOTINIB.EISAI WILL BE RESPONSIBLE FOR PRODUCT DISTRIBUTION IN JAPAN IN RA AND OTHER POTENTIAL FUTURE INDICATIONS.COMPANIES WILL JOINTLY COMMERCIALIZE MEDICINE IF APPROVED..

Royalty Pharma Announces Agreement To Purchase Future Royalties On Tazemetostat From Eisai For $330 Million And A $100 Million Initial Investment In Epizyme

Nov 5 (Reuters) - Royalty Pharma, Eisai Co Ltd <4523.T>::ROYALTY PHARMA ANNOUNCES AGREEMENT TO PURCHASE FUTURE ROYALTIES ON TAZEMETOSTAT FROM EISAI FOR $330 MILLION AND A $100 MILLION INITIAL INVESTMENT IN EPIZYME.ROYALTY PHARMA - PHARMAKON FUNDS TO INVEST UP TO $70 MILLION IN SENIOR-SECURED LOANS TO EPIZYME.ROYALTY PHARMA - AGREED TO PAY $330 MILLION TO PURCHASE EISAI CO., LTD.'S ROYALTIES ON FUTURE WORLDWIDE SALES OF TAZEMETOSTAT.ROYALTY PHARMA - DEAL HAS OPTIONS TO INVEST UP TO AN ADDITIONAL $100 MILLION IN EPIZYME COMMON STOCK.ROYALTY PHARMA - WILL MAKE AN UPFRONT PAYMENT OF $100 MILLION FOR SHARES OF EPIZYME COMMON STOCK BASED ON A PRICE OF $15 PER SHARE..ROYALTY PHARMA - EPIZYME HAS AN 18-MONTH OPTION TO SELL AN ADDITIONAL $50 MILLION OF ITS COMMON STOCK TO ROYALTY PHARMA.ROYALTY PHARMA - WILL MAKE ADDITIONAL PAYMENTS TO EPIZYME IF ANNUAL NET SALES OF TAZEMETOSTAT OUTSIDE OF JAPAN EXCEED CERTAIN THRESHOLDS.

Biogen Says Results From Analysis Of Aducanumab Positive For BAN2401

Oct 22 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN INC EXECUTIVE SAYS RESULTS FROM NEW ANALYSIS OF ADUCANUMAB ARE POSITIVE FOR OTHER ALZHEIMER’S DRUG BAN2401: CONF. CALL.BIOGEN INC EXECUTIVE SAYS FDA THOUGHT IT WAS "REASONABLE" TO FILE FOR REGULATORY APPROVAL OF ADUCANUMAB AFTER MEETING WITH CO: CONF CALL.

U.S. FDA Says Announcing Project Orbis, An Initiative Of The FDA Oncology Center Of Excellence

Sept 17 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS ANNOUNCING PROJECT ORBIS, AN INITIATIVE OF THE FDA ONCOLOGY CENTER OF EXCELLENCE.FDA SAYS UNDER PROJECT, FDA, AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION & HEALTH CANADA REVIEWED APPLICATIONS FOR 2 ONCOLOGY DRUGS.FDA - UNDER PROJECT, FDA GRANTED ACCELERATED APPROVAL TO LENVIMA IN COMBINATION WITH KEYTRUDA FOR TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA.

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Sept 13 (Reuters) - Biogen Inc <BIIB.O>::EISAI AND BIOGEN TO DISCONTINUE PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER'S DISEASE.BIOGEN INC - DISCONTINUATION OF STUDIES BASED ON DATA SAFETY MONITORING BOARD RECOMMENDATION.BIOGEN INC - DECISION IS BASED ON RESULTS OF A SAFETY REVIEW CONDUCTED BY DATA SAFETY MONITORING BOARD.BIOGEN INC - AS PART OF THIS DECISION, LONG-TERM EXTENSION OF PHASE II CLINICAL TRIAL OF ELENBECESTAT (STUDY 202) WILL ALSO BE DISCONTINUED.BIOGEN INC - DSMB RECOMMENDED TO DISCONTINUE BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER'S DISEASE TRIALS DUE TO UNFAVORABLE RISK-BENEFIT RATIO.BIOGEN INC - DETERMINATION DOES NOT IMPACT PROGRAM OF ANTI-AMYLOID BETA (AΒ) PROTOFIBRIL MONOCLONAL ANTIBODY BAN2401.BIOGEN INC - PHASE III CLARITY AD TRIAL OF BAN2401 WILL CONTINUE..BIOGEN INC - INVESTIGATORS ARE BEING INFORMED OF DECISION, THEY WILL BE CONTACTING THEIR STUDY PARTICIPANTS TO DISCONTINUE INVESTIGATIONAL TREATMENT.

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA

July 23 (Reuters) - Merck & Co Inc <MRK.N>::MERCK AND EISAI RECEIVE THIRD BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) COMBINATION TREATMENT.MERCK & CO INC- EFFICACY AND SAFETY OF COMBINATION OF KEYTRUDA PLUS LENVIMA HAS NOT BEEN ESTABLISHED.

Advanz Pharma Corp. Acquires International Rights To Two Medicines

April 1 (Reuters) - Advanz Pharma Corp <ADVZ.TO>::ADVANZ PHARMA CORP. ACQUIRES INTERNATIONAL RIGHTS TO TWO MEDICINES.ADVANZ PHARMA CORP - PROPOSED DEAL FOR $30 MILLION IN CASH PLUS APPROXIMATELY $3.3 MILLION FOR PURCHASED INVENTORY AND RELATED PREPAYMENTS..ADVANZ PHARMA CORP - ADVANZ PHARMA WILL PAY FOR ACQUISITION WITH CASH ON HAND..

Biogen, Eisai scrap Alzheimer's drug trials

March 21 (Reuters) - Biogen Inc <BIIB.O>::BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER’S DISEASE.BIOGEN INC - INDEPENDENT DATA MONITORING COMMITTEE ADVISES ADUCANUMAB UNLIKELY TO MEET PRIMARY ENDPOINTS, LEADING TO DECISION TO DISCONTINUE TRIALS.BIOGEN INC - DECISION TO STOP TRIALS IS BASED ON RESULTS OF A FUTILITY ANALYSIS CONDUCTED BY AN INDEPENDENT DATA MONITORING COMMITTEE.BIOGEN - AS PART OF THIS DECISION, EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED.BIOGEN INC - RESULTS INDICATED TRIALS WERE UNLIKELY TO MEET PRIMARY ENDPOINT UPON COMPLETION.BIOGEN INC - INITIATION OF ADUCANUMAB PHASE 3 SECONDARY PREVENTION TRIAL WILL BE ASSESSED WHILE DATA FROM ENGAGE AND EMERGE ARE FURTHER EVALUATED.BIOGEN INC - RECOMMENDATION TO STOP STUDIES WAS NOT BASED ON SAFETY CONCERNS..BIOGEN INC - EVOLVE PHASE 2 SAFETY STUDY AND LONG-TERM EXTENSION OF PRIME PHASE1B STUDY OF ADUCANUMAB WILL ALSO BE DISCONTINUED.BIOGEN AND EISAI TO DISCONTINUE PHASE 3 ENGAGE AND EMERGE TRIALS OF ADUCANUMAB IN ALZHEIMER'S DISEASE.

Eisai & Imbrium Therapeutics Reports U.S. FDA Accepts New Drug Application For Lemborexant For Treatment Of Insomnia

March 11 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND IMBRIUM THERAPEUTICS ANNOUNCE U.S. FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR LEMBOREXANT FOR THE TREATMENT OF INSOMNIA.EISAI CO LTD - PDUFA DATE IS SET FOR DECEMBER 27, 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up